ArticleNature communications2026
Accurate profiling of single-cell alternative transcript start sites by correcting RNA degradation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accurate profiling of single-cell alternative transcript start sites by correcting RNA degradation.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The generation of transcript variants via alternative utilisation of transcription start sites (TSSs) is a pivotal regulatory mechanism in physiological and pathological states. Recent advancements in 5' single-cell RNA sequencing (scRNA-seq) have enabled TSS analysis at the single-cell level. However, RNA degradation leads to non-uniform read coverage, posing a critical challenge that significantly compromises accurate TSS quantification of scRNA-seq data. To address RNA degradation and improve TSS quantification, we develop scATS (single-cell alternative transcription start site) to estimate RNA degradation at both isoform and sample levels, and provide TSS quantification with or without degradation correction. Application of scATS reveals dynamic and context-dependent regulation of TSSs in haematopoiesis and disease, providing additional information on TSS isoforms that aids cell clustering at a finer resolution. Furthermore, we establish a machine-learning pipeline, lung cancer relevance score (LRS), to identify TSSs associated with lung cancer. We analyse TSS isoforms of CCR6, CCR2 and RTKN2 in lung cancer cell lines and confirm that isoforms highly transcribed in lung cancer promote cell proliferation and migration. Combined, we present a robust tool to accurately quantify TSS by accounting for RNA degradation, a common issue that confounds transcript quantification, and experimentally demonstrate the important roles of TSS-mediated gene regulation in tumourigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.